Oaktree Acquisition Corp. III L (NASDAQ:OACCW)
| Market Cap | $249.98M+18.7% |
| Revenue (ttm) | $0 |
| Net Income | $6.75M+38.8% |
| EPS | $0.28+43.0% |
| Shares Out | 24.56M |
| PE Ratio | 37.77 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 10,003 |
| Open | $0.89 |
| Previous Close | $0.91 |
| Day's Range | $0.89 - $0.89 |
| 52-Week Range | $0.50 - $1.89 |
| Beta | 0.20 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | n/a |
About OACCW
Oaktree Acquisition Corp. III Life Sciences presently lacks significant commercial operations. Its primary focus is on completing a business combination, which could take the form of a merger, share exchange, asset acquisition, stock purchase, reorganization, or a similar corporate transaction, with one or more entities. The company aims to identify and acquire businesses operating in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors across North America and Europe. Incorporated in 2024, its base of operations is in Los Angeles, California.
$OACCW stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in OACCW holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by OACCW's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
OACCW Estimated quarterly lobbying spending
Source: U.S. Senate LDA
OACCW Revenue by Segment
| Cash held in Trust Account | $205.28M | 98.54% |
| Interest earned on cash held in Trust Account | $1.87M | 0.90% |
| Cash | $1.18M | 0.57% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New OACCW patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to OACCW from public contracts
Source: USAspending.gov
Bull Case vs Bear Case
AI-generated from OACCW’s recent data — informational, not investment advice